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Vitamin D accelerates clinical recovery from
tuberculosis: results of the SUCCINCT Study
[Supplementary Cholecalciferol in recovery from
tuberculosis]. A randomized, placebo-controlled,
clinical trial of vitamin D supplementation in
patients with pulmonary tuberculosis’
Nawal Salahuddin1*, Farheen Ali2, Zahra Hasan3, Nisar Rao4, Masooma Aqeel5 and Faisal Mahmood6
Abstract
Background: Vitamin D enhances host protective immune responses to Mycobacterium tuberculosis by suppressing
Interferon-gamma (IFN-g) and reducing disease associated inflammation in the host. The objectives of this study
were to determine whether vitamin D supplementation to patients with tuberculosis (TB) could influence recovery.
Methods: Two hundred and fifty nine patients with pulmonary TB were randomized to receive either 600,000 IU of
Intramuscular vitamin D3 or placebo for 2 doses. Assessments were performed at 4, 8 and 12 weeks. Early secreted
and T cell activated 6 kDa (ESAT6) and Mycobacterium tuberculosis sonicate (MTBs) antigen induced whole blood
stimulated IFN-g responses were measured at 0 and 12 weeks. Statistical comparisons between outcome variables
at 0 and 12 weeks were performed using Student’s t-test and Chi2 tests.
Results: After 12 weeks, the vitamin D supplemented arm demonstrated significantly greater mean weight gain
(kg) + 3.75, (3.16 – 4.34) versus + 2.61 (95% CI 1.99 – 3.23) p 0.009 and lesser residual disease by chest radiograph;
number of zones involved 1.35 v/s 1.82 p 0.004 (95% CI 0.15, 0.79) and 50% or greater reduction in cavity size 106
(89.8%) v/s 111 (94.8%), p 0.035. Vitamin D supplementation led to significant increase in MTBs-induced IFN-g
secretion in patients with baseline ‘Deficient’ 25-hydroxyvitamin D serum levels (p 0.021).
Conclusions: Supplementation with high doses of vitamin D accelerated clinical, radiographic improvement in all
TB patients and increased host immune activation in patients with baseline ‘Deficient’ serum vitamin D levels. These
results suggest a therapeutic role for vitamin D in the treatment of TB.
Trial registration: ClinicalTrials.gov; No. NCT01130311; URL: clinicaltrials.gov
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Background
Vitamin D is now known to be essential to Mycobacterium
tuberculosis (MTB) containment and killing through acti-
vation of 25-hydroxyvitamin D receptors (VDRs) present
on all immune cells. Stimulation of Toll-like receptors
(TLRs) on monocytes and macrophages by MTB antigens
leads to an up-regulation of VDRs. Binding of 1,25(OH)2
D3 activates VDRs and induces cathelicidin-mediated kill-
ing of Mycobacteria [1,2]. Susceptibility to tuberculosis
(TB) and risk of progression from infection to disease,
tends to occur more often in patients with low 25- hydro-
xyvitamin D levels [3-5] while, close contacts of TB
patients display a 5-fold increased risk of contracting TB
with each relative 1–log decrement in 25- hydroxyvitamin
D level [6]. Historically cod liver oil and sunshine, both
excellent sources of 25-hydroxyvitamin D, were used for
the treatment of TB. More recently, single doses of
25-hydroxyvitamin D have been demonstrated to enhance
mycobacterial killing [7]. However two recent Vitamin D
supplementation trials failed to demonstrate any benefit
[8,9] possibly due to the low doses used. We hypothesized
that supplementation with therapeutic doses of vitamin D
in patients with active TB, may improve outcomes. Our
study objectives were to determine the effects of vitamin




This was a randomized double blinded, multi-centre,
placebo-controlled clinical trial. The study was approved
by the institutional review boards of the participating cen-
tres; Aga Khan University Hospital (ERC approval no.
1238-Med/ERC-09) and Ojha Institute of Chest Diseases,
Dow University Hospital (IRB-94/DUHS-09) and is listed
on clinicaltrials.gov (NCT01130311). The trial was funded
through a grant obtained from the Aga Khan University
Research Council (URC grant No. 0000058579). The study
was conducted from October 2009 to July 2010 with en-
rolment of the first participant in October 2009 and last
participant in April 2010. The protocol was made available
at clinicaltrials.gov in May 2010. All patients provided
written, informed consent prior to participation. Consecu-
tive adult patients (≥16 years) with smear positive, active
pulmonary TB diagnosed within one week and enrolled at
outpatient TB clinics were included. Based on clinical
history taking and clinical records, patients with extra-
pulmonary TB, human immunodeficiency virus (HIV)
infection, hepatic disease, renal failure, malignancy, dia-
betes mellitus, pregnancy, sarcoidosis, hyperparathyroidism
or those taking any corticosteroids, immunosuppressive
agents, thiazide diuretics or drugs known to interfere with
vitamin D levels (phenytoin, phenobarbital, carbamazepine,
theophylline) were excluded from the study.
Primary and secondary outcome variables
The primary outcome variables were differences in weight
gained and resolution of chest radiograph abnormalities.
Secondary outcomes were differences in whole blood cell
antigen-stimulated Interferon-gamma(IFN-g) responses,
differences in sputum conversion rates and improvements
in the TB score. An ad hoc analysis looked at the differ-
ences in the cytokine response, and clinical recovery based
on differences in baseline vitamin D status.
Measurements
Baseline clinical data, chest radiographs, sputum and
blood samples for 25 hydroxyvitamin D assay and cytokine
analysis were collected. The randomization sequence was
generated by the Dept. of Pharmacy, Aga Khan University,
who were responsible for dispensing the study drug/pla-
cebo. The study co-ordinator and physician available at the
study site enrolled participants who were eligible. All
patients continued to receive Directly Observed Therapy
(DOTS) with 2 months of 4 antituberculous drugs
[Isoniazid, Rifampicin, Ethambutol and Pyrazinamide] fol-
lowed by 6 months of Isoniazid and Ethambutol. Eligible
patients were screened, enrolled and randomized by a
computer-generated stratified, random assignments list
(block randomization). The 2 study arms were either admi-
nistered 600,000 IU of intramuscular vitamin D3 (cholecal-
ciferol) for 2 doses one month apart or an equivalent
volume of normal saline matched for colour. Doses were
given at enrolment and repeated 4 weeks from baseline.
This dosage formulation of vitamin D is as recommended
for vitamin D supplementation by the Pakistan Endocrine
Society [personal communication]. The patient, primary
physicians, investigator physicians, study coordinator, site
assistants were blinded to the treatment allocation.
Clinical assessments and sputum microscopic examina-
tions were performed at all visits (0, 4, 8 and 12 weeks of
therapy). Chest radiographs and blood samples for cyto-
kine assays were obtained at 0 and 12 weeks. Clinical
examination was used to calculate a TB score [10] for all
visits. The TB score is a validated assessment tool devel-
oped to objectively measure change in the clinical status
of TB patients. Its components include self-reported
symptoms (cough, shortness of breath, night sweats, chest
pain, haemoptysis), clinical signs (tachycardia, pallor, fever,
auscultatory findings) body mass index (BMI) and
mid-upper arm circumference (MUAC). Mid Upper Arm
Circumference (MUAC) was recorded to an accuracy of
0.5 cm at the mid-point of the acromion and the olecra-
non process over the biceps muscle of the non-dominant
arm, using a non-stretchable measuring tape. Height was
recorded in metres, and weight in kilograms using a
standard weighing machine at all visits. Body Mass Index
(BMI) = weight (kg)/height (m2). The TB score achieved
can range from 0–13. TB scores were further divided into
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3 severity classes; Severity Class I (TB score 0 to 5), Class
II (TB score 6 – 7) and Class III (TB score ≥ 8). Baseline
25 hydroxyvitamin D levels were measured and divided
into ‘Optimal’ > 30 ng/ml, ‘Insufficient’ 20–30 ng/ml and
‘Deficient’ < 20 ng/ml.
Chest X-rays were interpreted independently by 2 con-
sultant pulmonologists who were blinded to the treatment
allocation process. Three separate methods of disease
categorization were employed. This included classification
into ‘minimally’, ‘moderately’ and far advanced categories
of radiographic infiltrates [11,12]. Secondly, cavity size
and change in size from 0 to 12 weeks was recorded.
Thirdly, the bilateral lung fields were divided in to 3 zones
(6 total) and disease extent was recorded as ‘Zone involve-
ment’ (Table 1).
At each follow up visit patients were asked about symp-
toms of hypercalcemia i.e. nausea, vomiting, abdominal
pain, confusion or renal colic. Calcium (and albumin in
patients with BMI < 18) was measured at 12 weeks from
enrolment.
Whole blood assay and IFN-g measurements
Recombinant antigen early secreted and activated target
(ESAT) -6 kDa and M. tuberculosis H37Rv whole sonicate
(MTBs) were provided through the NIH tuberculosis vac-
cine testing and reagent material contract (NO1-A1-40091)
awarded to Colorado State University, USA. Mycobacterial
antigen stimulated responses in study subjects of the
placebo group (n = 127) and vitamin D intervention group
(n = 132) were tested at the time of recruitment prior to
any anti-tuberculosis treatment or supplementation and
subsequently after treatment (weeks 12 of inclusion).
Diluted whole blood cells were stimulated with 5 mcg/ml
ESAT6 and 10 mcg/ml MTBs and IFN-g was measured
in cell culture supernatants collected at 6 days post-
stimulation as described previously [13]. All samples were
set up in replicates. Samples were centrifuged to collect any
cellular debris, aliquoted and stored at −70 C until tested.
IFN-g was detected in cellular supernatants by using
standards and ELISA reagents obtained from Endogen
(Rockford, IL, USA). Cytokines were measured using a
sandwich ELISA technique according to the manufac-
turer’s instructions and as reported previously [13]. Re-
combinant human cytokine was used to obtain a dose
response curve with a range of detection from 3.9-
1000 pg/ml.
Biochemical assays
Serum 25-hydroxy25-hydroxyvitamin D3 was measured
using the electrochemiluminescence immunoassay “ECLIA”
(Roche Diagnostics GmbH, D-68298 Mannheim). Serum
calcium and albumin was measured by colorimetric assay
(Roche Diagnostics GmbH, D-68298 Mannheim) and
colorimetric determination of serum albumin using bromo-
cresol green at pH 4.20 (Merck, Pakistan).
Clinical assessments and sputum microscopic examina-
tions were performed at 0, 4, 8 and 12 weeks of therapy.
Chest radiographs and blood samples for cytokine assays
were obtained at 0 and 12 weeks. At each follow up visit
patients were asked about symptoms of hypercalcemia i.e.
nausea, vomiting, abdominal pain, confusion or renal colic.
Serum 25-hydroxy 25-hydroxyvitamin D3, calcium (and
albumin in patients with BMI < 18) were measured at
12 weeks from enrolment. For the sample size calculation,
we hypothesized that vitamin D supplementation could re-
sult in a weight gain equal to or greater than 10% of the
mean weight gain in the placebo group [8] and a 15% dif-
ference in radiographic improvement between the 2
groups. We estimated we would need 125 patients in each
arm to reject the null hypothesis with a power of 80
percent and a 5% level of significance. We estimated a 15%
risk of hypercalcemia after supplementation in the 25-
hydroxyvitamin D arm, based on a previous study by Wejse
et al. [9] and therefore estimated we would need 60 pa-
tients in each group for a power of 80% and 5% level of sig-
nificance. The primary outcome variable was differences in
weight gained and resolution of chest radiographic abnor-
malities. Secondary outcomes were differences in IFN-g
responses, differences in sputum conversion rates and
improvements in TB score. An ad hoc analysis looked at
differences in the cytokine response and clinical recovery in
groups stratified as ‘Optimal’, ‘Insufficient’ and ‘Deficient’ by
vitamin D levels at enrolment.
Analysis
Data was analysed by ‘intention-to-treat’ analysis. Outcome
variables were reported by either their means or medians
and with ranges or standard deviations. Statistical compari-
sons at 0 and 12 weeks were performed using Student’s
t-test for continuous variables and Pearson Chi-squared
tests for categorical variables. IFN-g responses pre- and
post-treatment between baseline 25-(OH)hydroxy vitamin
D levels and TB severity groups were compared using the
Kruskal-Wallis non-parametric test. A two-sided p value of
< 0.05 was considered significant. Data was analysed using
SPSS version 17.0. An interim safety analysis looking for
differences in mortality was carried out with the institu-
tional research office at 3 months. No differences in mortal-
ity rates were identified between the two study groups.
Results
Description of the study
Three hundred and thirty seven patients were screened for
eligibility; 259 patients were enrolled and randomized to
the 2 treatment arms; 132 in the 25-hydroxyvitamin D sup-
plementation arm and 127 in the placebo arm, as illustrated
in Figure 1. The study was conducted from October 2009
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to July 2010 with enrolment of the first participant in Octo-
ber 2009 and last participant in April 2010. One hundred
and nineteen patients in each arm completed the study
with a default/dropout rate of 8.1%. Three patients died
during the study period; 2 in the 25-hydroxyvitamin D
intervention arm and 1 in the placebo. Deaths in the vita-
min D arm included 1 due to rapidly progressive respira-
tory failure of undetermined etiology within 2 weeks of
inclusion and 1 in an automobile accident. One patient died
of malaria in the placebo arm.
Study findings
Baseline characteristics of the 2 study populations are
shown in Table 1. The two arms did not differ significantly
except for a higher number of patients with fever in the
placebo arm, 49 v/s 68 (p 0.008). Mean age for the total
population was 28 ± 13.6 years and 135 subjects (49.5%)
had + 3 AFB on sputum smear microscopy. Mean 25-
hydroxyvitamin D levels for the entire population were in
the ‘Insufficient’ range; 21.3 ng/mL ± 9.78. 25 hydroxy-
vitamin D levels were noted to be lower in patients with
greater severity of chest radiographic involvement at
baseline [216 (83%) v/s 43 (16%), p 0.012], in females
[67 (56.7%) v/s 49 (34.7%) had levels < 20 ng/mL, p 0.001]
and in younger patients [p 0.004]. There were no signifi-
cant associations between baseline 25-hydroxyvitamin D
levels and sputum AFB load (p 0.77), or TB severity score
(p 0.26). There was a trend towards greater association of
haemoptysis with lower levels of vitamin D (p 0.049).
Changes in measured clinical variables after 12 weeks
of antituberculous therapy are shown in Table 2.
Changes in serum 25 hydroxyvitamin D levels in the
two groups is shown in Additional file 1: Figure S1.
Table 1 Baseline characteristics in the vitamin D and







Age (years), Mean ± SD 27.8 ± 13.2 28.3 ± 14.1
Gender, Men 71 (53.8) 70 (55.1)
Weight (kg), Mean ± SD 45.2 ± 7.6 45.6 ± 9.0
BMI, Mean (range) 17.2 (11–25) 17.3 (11–27)
MUAC (cm), (range) 21.2 (14–30) 21.1 (15–32)
Disease Symptom(s)
present
Cough 127 (96.2) 125 (98.4)
Haemoptysis 30 (22.7) 34 (26.8)
Dyspnoea 84 (63.6) 85 (66.9)
Chest pain 84 (63.6) 84 (66.1)
Night sweats 69 (52.3) 55 (43.3)
Pale conjunctiva 70 (53) 67 (52.8)
Tachycardia 87 (65.9) 86 (67.7)
Fever 49 (37.1) 68 (53.5)
Crepitations 50 (37.9) 38 (29.9)
Rhonchi 19 (14.4) 21 (16.5)
Reduced breath sounds 26 (19.7) 20 (15.7)
TB score, Mean ± SD, 95 CI 6.68 ± 2.04, 6.3-7.03 6.85 ± 2.50, 6.4-7.29
Distribution by Severity
Class/TB score*
Class I/0 – 5 32 (24.2) 40 (31.5)
Class II/6 – 7 51 (38.6) 41 (32.3)
Class III/≥ 8 49 (37.1) 46 (36.2)
Serum-25-(OH)D3 levels;
Mean, (SD)
20.58 ± 8.51 22.87 ± 10.33
25(OH)D3 >30 ng/ml
(Optimal)
18 (13.6) 25 (19.7)
25(OH)D3 20-30 ng/ml
(Insufficient)
46 (34.8) 54 (42.5)






10 (7.6) 13 (10.2)
Moderately Advanced
disease
77 (58.3) 62 (48.8)
Far Advanced disease 45 (34.1) 52 (40.9)
No Cavity 7 (5.3) 4 (3.1)
Cavity size < 4 cm 60 (45.5) 59 (46.5)
Cavity size ≥ 4 cm 65 (49.2) 64 (50.4)
No. of zones involved 3,
Mean ± SD
3.61 ± 1.40 3.64 ± 1.48
Sputum microbial load
(microscopy)2
Table 1 Baseline characteristics in the vitamin D and
placebo study arms (N = 259) (Continued)
Scant, 1–9 AFB/100 fields 4 (3.0) 2 (1.6)
+1, 10–99 AFB/100 fields, 36 (27.3) 34 (26.8)
+2, 1–10 AFB/50 fields, 25 (18.9) 23 (18.1)
+3, >10 AFB/20 fields, 67 (50.8) 68 (53.5)
IFN-g levels (pg/ml)
mean ± SD
Unstimulated levels 0.2 ± 2.6 0 ±0
ESAT6-stimulated 413 ±977 303 ±804
MTBs-stimulated 2826 ±1391 2858 ±1337
MUAC Mid Upper Arm Circumference; BMI Body Mass Index; s-25-(OH)D3 =
serum 25- hydroxyvitamin D3.* Severity Class (TB score) [10];
1Chest X ray
classification: Each hemi-lung was divided into 3 zones (total 6 lung zones):
active parenchymal and cavitary disease, exclusive of old fibrotic scarring,
recorded as ‘zone involvement’ [11,12]. 2Diagnostic Standards and
Classification of Tuberculosis, National Tuberculosis Association of the USA,
1961. Data are presented here as number (%), unless stated otherwise.
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After 12 weeks of antituberculous therapy, the 25-
hydroxyvitamin D supplemented arm had a mean weight
gain (kg) of; + 3.75 (3.16 – 4.34) v/s + 2.61 (95% CI 1.99 –
3.23) in the placebo arm (p 0.009) and in BMI; + 1.39
(95% CI 1.15 – 1.63) v/s + 0.95 (95% CI 0.71 – 1.19) in
the placebo arm (p 0.01). Interpretation of chest radio-
graphs at 12 weeks showed that the mean number of
zones involved in the vitamin D arm were 1.35 v/s 1.82
zones in the placebo arm (p 0.004) (95% CI 0.15, 0.79).
106 (89.8%) patients in the vitamin D arm had 50% or
more reduction in cavity size v/s 111 (94.8%) in the pla-
cebo arm (p 0.035).
Evaluation of sputum microscopy data for the study
subjects showed that 134 (60%) patients were sputum
smear negative by week 4 of therapy. Overall, no signifi-
cant differences were observed in sputum smear conver-
sion rates (Additional file 2: Figure S2) or TB scores at
weeks 4 (p 0.18), 8 (p 0.89) and 12 (p 0.16) between the 2
study arms. On post hoc analysis, patients in the vitamin
D arm and serum < 30 ng/mL (‘Insufficient’ and ‘Deficient’
groups) at enrolment had significantly greater improve-
ments in TB severity scores compared to patients with
normal baseline 25-hydroxyvitamin D levels; p 0.014.
Additionally, the subgroup in the supplementation arm
that had baseline ‘Insufficient’ levels showed a trend to-
wards lower number of zones involved on chest radiograph
(p 0.054) and higher sputum smear clearance (p 0.05) how-
ever, this difference was not statistically significant.
Mycobacterial-antigen stimulated IFN-g responses in
placebo and treatment groups
We first determined mycobacterial antigen-stimulated
IFN-g responses at baseline in the placebo group to in-
vestigate possible effects in cytokine secretion profiles
due to variations in disease severity in patients. We
observed that ESAT6- induced IFN-g responses did not
differ between patients classified according to their TB
scores into Class I, II and III disease (p = 0.996, Kruskal-
Wallis test, Figure 2A). Also, M. tuberculosis sonicate
(MTBs) – induced IFN-g was similar between patients
of with Class I, II and III TB (p = 0.257, Kruskal-Wallis
test, Figure 2B).
As study subjects had variable circulating levels of
25-hydroxyvitamin D and vitamin D suppresses IFN- γ
production in the host.1 we classified patients into those
with Optimal, Insufficient or Deficient 25-hydroxyvitamin
D levels at baseline and then determined mycobacter-
ial antigen-stimulated IFN-g responses to see if there
was any association between serum 25 hydroxyvitamin
D levels and IFN-g responses in the placebo group.
ESAT6 stimulated whole blood cell IFN-g secretion
of groups with Optimal, Insufficient or Deficient
25-hydroxyvitamin D levels did not differ (p = 0.503,
Kruskal-Wallis analysis), Figure 2C. MTBs-induced
IFN-g secretion was also comparable between the dif-
ferent vitamin D groups (p = 0.608, Kruskal-Wallis
analysis), Figure 2D.
Figure 1 Study Flowchart. Study Drug (Cholecalciferol) and Placebo (Normal Saline) matched for colour and volume of contents. 2 ‘Completed
treatment’; administration of 2 doses of study drug/placebo (over first 2 months), with follow up assessments complete at all visits over a total
duration of 3 months. * Includes all patients who completed treatment at end of 3 months, as well as those who died during, or defaulted from,
treatment before completion (indicated for each treatment arm). Flow Diagram adapted from the CONSORT 2010 Statement: updated guidelines
for reporting parallel group randomized trials.
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Increased MTBs-induced IFN-g responses with
supplementation in those with Deficient 25-hydroxy
vitamin D levels
We subsequently determined mycobacterial antigen-
stimulated IFN-g responses prior to initiation of therapy
(0 week) and after 12 weeks of therapy in both placebo
and intervention arms of the study. It was observed that
MTBs-induced IFN-g levels in the 25-hydroxyvitamin D
intervention group were increased post-therapy (p = 0.022,
Figure 3). However, no difference was observed in MTBs-
induced IFN-g levels compared between 0 and 12 weeks
in the placebo group. When ESAT6- stimulated IFN-g
responses were considered no difference was observed be-
tween 0 and 12-week responses in either the placebo or
intervention arms (Additional file 3: Table S1).
Further, we investigated factors which may play a role
in determining the increase in MTBs- stimulated IFN-g
responses in the intervention group post-therapy and
further analysed this data after sub-classification of
patients according to disease severity and also their
baseline serum level of 25-hydroxyvitamin D levels.
M. tuberculosis sonicate antigen-induced IFN-g responses
are increased as a consequence of treatment in patients
with more severe TB
It was observed that MTBs – induced IFN- γ res-
ponses significantly increased in patients with Class III
disease after 12 weeks of anti-tuberculous therapy in
both the placebo (p = 0.001) and 25-hydroxyvitamin D
treatment arm (p = 0.034), Figure 4A-B. No such post-
treatment increase was observed when ESAT6-induced
IFN- γ responses in the study subjects were compared
(Additional file 4: Table S2).
Supplementation increases in M. tuberculosis sonicate
induced IFN-g responses in patients with deficient
25-(OH) vitamin hydroxyvitamin D levels
To investigate the effect of 25-(OH) vitamin D supplemen-
tation in patients with different serum 25-hydroxyvitamin
D levels we compared subjects in both arms of the study
classified into those with Optimal, Insufficient and Deficient
25-hydroxyvitamin D levels. Increase in MTBs-induced
IFN-g secretion after therapy occurred only in subjects with
Deficient 25-hydroxyvitamin D levels (p = 0.021, Figure 5B)
in the drug intervention group but not in the placebo
group, Figure 5A. ESAT6 induced – IFN- γ responses at 0
and 12 weeks did not differ in either the placebo or
25-hydroxyvitamin D treatment arms (Additional file 5:
Table S3).
Discussion
We have shown that therapeutic doses of Vitamin D (in the
form of 2 doses of cholecalciferol at monthly intervals),
given to patients with active pulmonary TB, can lead to
proportionately greater weight gain and more rapid radio-
graphic clearing of disease as compared to placebo.
It has recently been proposed that vitamin D acceler-
ates resolution of host inflammatory responses and this
may contribute to the improvement observed in vitamin
Table 2 Changes in measured clinical variables from baseline to study completion
Measured disease parameter(s) Randomization p-value
(95% CI)Drug intervention (n = 132) Placebo intervention (n = 127)
TB Severity (clinical assessment)
Mean Δ in TB score (points) ± SD, (95 CI) - 3.19 ± 2.37, (−3.61, -2.75) - 2.79 ± 2.44, (−3.23, -2.34) 0.198
Mean Δ in weight (kg), (95% CI) + 4.02, (3.18 – 4.86) + 2.61, (1.99 – 3.23) 0.007
Mean Δ in BMI, (95% CI) + 1.48, (1.17 – 1.78) + 0.96, (0.72 – 1.20) 0.008
Mean Δ in MUAC (cm), (95% CI) + 1.34, (0.74 – 1.64) + 0.97, (0.68 – 1.26) 0.079
Chest X-Ray Involvement
Mean no. of zones1 involved ± SD 1.35 ± 1.13 1.82 ± 1.35 0.004
Sputum Smear
Smear Conversion, no. (%) 2 108 (81.8) 103 (81.1) 0.39
IFN-g levels (pg/ml) mean ± SD
Unstimulated levels 3.9 ±28.7 4.3 ± 45.2 0.325
ESAT6-stimulated* 387 ±920 206 ±665 0.077
MTBs-stimulated* 3092 ±1363 2987 ±1510 0.497
MUAC Mid Upper Arm Circumference; BMI Body Mass Index; 95 CI 95% Confidence Interval; SD Standard Deviation; s-25-(OH) D3 = serum 25-hydroxyvitamin D3.
1 Division of bilateral ling fields into a total of 6 zones (3 per each lung, ‘zone involvement’ = active parenchymal and cavitary disease, exclusive of old fibrotic
scarring. 2 Includes all patients who were expectorating at baseline, and claimed ‘unable to expectorate’ at completion of treatment 12 weeks later. ESAT6 early
secreted and T cell activated antigen-6 kDa; MTBs Mycobacterium tuberculosis whole sonicate antigen.
*Denotes cytokine levels after subtraction of background from unstimulated cells.
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D supplemented TB therapy [14]. Here we illustrate
that vitamin D supplementation enhances mycobacterial-
antigen induced IFN-g secretion in patients with Deficient
25-hydroxyvitamin D levels, thereby improving cell me-
diated immunity against M. tuberculosis.
25-hydroxyvitamin D is recognized as an important
immune-modulator in TB. 1, 25 (OH) 2 D3 binding with
VDRs activates cathelicidin-mediated mycobacterial killing
[1,2] whilst 25-hydroxyvitamin D deficiency increases the
susceptibility and vulnerability to TB [3,4]. G interferon
(IFN-γ) is a proinflammatory cytokine, which plays a
critical role in resistance to MTB infection [15]. Infection
with MTB induces T lymphocytes, natural killer cells and
alveolar macrophages to express IFN-g and induces
IFN-γ-driven monokines that regulate granuloma for-
mation [16]. IFN-g responses have been shown to be
depressed in patients with advanced forms of tuberculosis
[17]. We observed a significant improvement in MTBs-
induced IFN-g responses after 12 weeks of ATT in vitamin
D ‘Deficient’ patients who received 25-hydroxyvitamin.
This is the first vitamin D supplementation study where
groups have been stratified into those with differing dis-
ease severity and also according to their baseline serum
25-hydroxyvitamin D levels.
Figure 2 Mycobacterial-antigen stimulated IFN-g responses in TB patients according to disease severity and circulating
25-hydroxyvitamin D levels. Diluted whole blood cells were stimulated with ESAT6 and M. tuberculosis sonicate (MTBs) and IFN-g measured in
cell supernatants after 6 days of culture. The graphs depict IFN-g responses in patients classified into severity according to their TB scores (a-b);
Severity Class I (TB score 0 to 5), Class II (TB score 6 – 7) and Class III (TB score≥ 8) in response to stimulation with (a) ESAT6 and (b) MTBs, or
according to their vitamin D levels (c-d); Optimal (>30 nmol/ml), Insufficient (20–30 nmol/ml) or Deficient (< 20 nmol/ml) in response to
stimulation with (c) ESAT6 and (d) MTBs. The box and whiskers plots depict cytokine responses in the 10th to 90th percentiles with the horizontal
bar indicating the median levels of each group.
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Previous reports by Ulrichs et al. have shown that IFN-g
producing cells against ESAT6 in tuberculosis patients in-
crease post-tuberculosis therapy [18]. However, we were
unable to demonstrate any difference in ESAT6-induced
IFN- γ responses between patients prior to and post-treat-
ment. This is in concordance with a recent report by
Coussens et al. [14] that did not show any change in
ESAT-6 induced IFN-g in patients post-antituberculous
therapy. ESAT6 and culture filtrate protein 10 (CFP10) are
both encoded by the region of difference 1 (RD1) present
in M. tuberculosis and in virulent M. bovis, but absent
from M. bovis BCG and environmental mycobacteria [19].
Antigen based interferon g release assays (IGRAs) have a
varied sensitivity in endemic and non-endemic settings, at-
tributable to exposure to environmental mycobacterial
and M. tuberculosis and resulting T cell IFN-g responses
[20]. M. tuberculosis whole sonicate (MTBs) contains
cross reactive epitopes to M. bovis BCG vaccine strain and
environmental mycobacteria and therefore, can induce po-
tent cytokine responses from T cells, macrophages and
other polymorphonuclear cells. MTBs induced responses
have been useful in differentiating severity of disease in
TB. Patients with advanced disease display decreased IFN-
g responses [13]. We observed that after 12 weeks of ATT,
the Class III severity groups had significant increases
in MTBs-induced IFN-g responses. This increase in
mycobacterial-antigen induced IFN-g responses represents
host immunity in patients with advanced pulmonary dis-
ease, possibly leading to improved resolution of the
Figure 3 MTBs-induced IFN-g secretion is increased in the
Vitamin D treatment arm after 12 weeks of anti-tuberculous
therapy. Diluted whole blood cells were stimulated with
M. tuberculosis sonicate (MTBs) and IFN-g measured in cell
supernatants after 6 days of culture. The box and whiskers plots
depict cytokine responses in the 10th to 90th percentiles with the
horizontal bar indicating the median levels of each group.
‘*' Denotes values significantly different p < 0.05 between levels at 0
and 12 weeks respectively as determined by paired t test analysis.
Figure 4 MTBs- stimulated IFN-g levels are increased post-therapy in TB patients with deficient more severe TB. Whole blood cells were
stimulated with MTBs and IFN-g measured in cell supernatants and compared between patients classified into TB severity classes I, II and III.
Responses at 0 and 12 weeks were compared in each group by paired t test analysis. The box and whiskers plots depict cytokine responses in
the 10th to 90th percentiles with the horizontal bar indicating the median levels of each group. a, Placebo arm b, Drug intervention arm.
‘*' Denotes p <0.05 between levels at 0 and 12 weeks respectively.
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disease. Further analysis of to determine the impact of
host 25- hydroxyvitamin D levels on immune recovery
revealed that in patients who received vitamin D supple-
mentation, MTBs-induced IFN-g secretion was signifi-
cantly increased after 12 week of anti-tuberculous therapy
only in patients who had ‘Deficient’ 25-hydroxyvitamin D
levels (< 20 ng/mL) at initiation of treatment whilst this
immune recovery was absent for TB patients with ‘Defi-
cient’ 25- hydroxyvitamin D levels in the placebo group.
This data suggests a role for 25-hydroxyvitamin D supple-
mentation in boosting host immunity particularly in those
with deficient 25 hydroxyvitamin D levels. It is possible
that only patients with ‘Deficient’ 25 hydroxyvitamin D
levels showed an improvement perhaps due to a critical
level of 25-hydroxyvitamin D required by the host for op-
timal activation of IFN-g secretion and because this limit
was already reached in the other 25-hydroxyvitamin D
groups where no enhancement of mycobacterial antigen-
induced IFN-g response was observed.
Weight gain is routinely followed as an outpatient
marker of clinical improvement in TB and we observed
improvements in clinical status; i.e.; weight gain com-
pared to the placebo group. This corresponds with the
earliest reports of the benefits of vitamin D in TB
patients published in 1848 [21] that describes disease ar-
rest, weight gain and reduction in mortality in patients
with TB treated with cod liver oil compared to standard
therapy alone. More recently, Martineau et al. demon-
strated that a single oral dose of 2.5 mg (100,000 IU) of ergo-
calciferol significantly reduced growth of mycobacteria [7]. A
randomized, placebo controlled study on 67 Indonesian
patients, by Nursyam et al. [22] reported that pulmonary
TB patients given 420,000 IU of vitamin D over 6 weeks
had significantly higher sputum conversion rates as com-
pared to placebo (p 0.002). Martineau et al. [8] showed that
100,000 IUs of 25-hydroxyvitamin D3 supplementation sig-
nificantly improved sputum conversion rates in patients
with the Taq1 25-hydroxyvitamin D receptor polymorph-
ism of the tt genotype. We speculate that this occurred due
to broader effects of 25-hydroxyvitamin D on muscle, vas-
cular and homeostasis [23-26].
We also found that the vitamin D treatment group
had lesser disease (compared to placebo) by chest radi-
ography after 12 weeks of therapy. This finding is con-
sistent with a recent small placebo controlled trial on 24
children in Egypt that reported greater clinical and
radiographic recovery after 1000 IUs of oral vitamin D
supplementation [27] and a case report of an African –
American patient with refractory, drug sensitive TB who
improved only after being treated with 1,200,000 IU of
ergoclaciferol [28].
However, two recently published large randomised, con-
trolled trials by Martineau [8] and Wejse et al. [9] found no
difference in clinical outcomes or mortality after 10 mg
(400,000 IU) of 25-hydroxyvitamin D3 and 300,000 IUs of
cholecalciferol or placebo were given to 146 pulmonary TB
patients in London, United Kingdom and 365 TB patients
in Guinea-Bissau. It maybe speculated that the differences
in response to 25-hydroxyvitamin D seen between our
study and Wejse’s could be due to variations in VDR
Figure 5 MTBs- stimulated IFN-g levels are increased post-therapy in TB patients with deficient Vitamin D levels. Whole blood cells were
stimulated with MTBs and IFN-g measured in cell supernatants at 6 days post-stimulation. Vitamin D levels >30 ng/ml, Optimal; 20–30 ng/ml,
Insufficient; <20 ng/nl, Deficient. a, Placebo arm b, Drug intervention arm. The box and whiskers plots depict cytokine responses in the 10th to
90th percentiles with the horizontal bar indicating the median levels of each group. ‘*' Denotes p <0.05 between levels at 0 and 12 weeks
respectively as determined by paired t test analysis.
Salahuddin et al. BMC Infectious Diseases 2013, 13:22 Page 9 of 11
http://www.biomedcentral.com/1471-2334/13/22
polymorphisms, variability in 25-hydroxyvitamin D dosages
or differing levels of baseline serum 25-hydroxyvitamin D
levels.
We found 25-hydroxyvitamin D supplementation to
be very safe, even in patients without deficiency. Only
two patients in the vitamin D arm died during the study;
one death was due to respiratory failure occurring within
the initial 2 weeks of antituberculous therapy. It can be
speculated whether this was a paradoxical response lead-
ing to acute lung injury.
We used a ‘higher’ dose than the 2 recent negative stud-
ies reported by Wejse and Martineau et al., but closer to
therapeutic recommendations [29-31]. We speculate that
this may account for the differences observed in the 2
groups at 12 weeks. We consider it a limitation of our
study that we were unable to follow our patients to the
end of treatment (6 months). It is possible that the benefits
of 25-hydroxyvitamin D replacement may become more
apparent between the groups with longer follow up.
Another limitation of our study is that we did not col-
lect information on dietary intakes However the study
groups were well matched at enrolment and represented
a variety of socioeconomic and ethnic groups, which
may reduce the possibility that one study arm was dis-
proportionately better nourished.
Conclusion
In summary, this study proposes that high dose vitamin
D supplementation can lead to a more marked clinical
and radiological recovery in all patients with pulmonary
TB and boost host immune responses in patients defi-
cient in 25-hydroxy vitamin D.
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